NEW YORK (GenomeWeb News) – Horizon Discovery announced on its website today that it has inked a collaborative agreement with Janssen Pharmaceutica division Ortho Biotech Oncology Research & Development.
Cambridge, UK-based Horizon said that the deal covers the licensing of certain of its X-MAN cell lines including major cancer-causing genes and their matched normal genetic backgrounds. Horizon said that the cell lines could help the J&J unit to gather information related to selectivity and mode of action of drug candidates.
Janssen will pay Horizon an undisclosed up-front fee and renewal fees during the term of the alliance. The firms will begin working together this month.